Non-small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is a frequently diagnosed cancer type and a leading cause of cancer-related death.1
Treatments for NSCLC include surgery, chemotherapy, radiation therapy, and targeted therapy.2 The treatment landscape of resectable NSCLC has been enhanced for patients with NSCLC following the approval of systemic treatments, such as atezolizumab, osimertinib, pembrolizumab, and nivolumab combined with chemotherapy.3,4
Many clinical challenges persist in the face of these advances. For example, factors such as abnormal antigen presentation, functional gene mutation, and the tumour microenvironment can contribute to treatment resistance. The mechanisms of acquired resistance to these therapies are under investigation.3
Learning zones and other resources
Can telemedicine palliate patients with NSCLC?
Presented by Dr Joseph Greer (Massachusetts General Hospital Cancer Center, USA) at ASCO 2024, read outcome data from the REACH PC trial for comparing the effectiveness of early palliative care delivered through video with in-person care for patients with advanced NSCLC
Osimertinib for EGFR-mutated NSCLC – LAURA trial
Presented by Dr Suresh S Ramalingam (Winship Cancer Institute of Emory University, USA) at ASCO 2024, read LAURA outcome data for osimertinib for managing unresectable stage 3 EGFR-mutated NSCLC without progression.
ASCO 2024 A high-level overview
From ASCO 2024, read Dr Ben Gallarda’s overview of ASCO’s commitment to palliative care, artificial intelligence, and coordination with organizations.
Symposium on refractory multiple myeloma, COMy 2023
Watch our expert panel discussion on the management of relapsed and refractory multiple myeloma (RRMM) in older and frail adults.
How can poor-quality clinical trials impact clinical decision-making?
Explore why a cautious approach is warranted when interpreting trial results.
Related news and insights
Guidelines
References
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249.
- NCI, 2024. https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq. Accessed May 20, 2024.
- Houda I, Dickhoff C, Uyl-De Groot CA, Damhuis RAM, Reguart N, Provencio M, et al. Challenges and controversies in resectable non-small cell lung cancer: a clinician’s perspective. The Lancet. 2024;38:100841.
- Houda I, Dickhoff C, Uyl-De Groot CA, Reguart N, Provencio M, Levy A, et al. New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe. The Lancet. 2024;38:100840.